Oct 2026· Oriental Journal of Chemistry· 0 citations· 14 references
TL;DR
The current GWAS findings in several common cancers, recent methodological and analytical developments of GWAS studies that help improve the understanding of cancer biology, knowledge gained from GWAS findings for potential clinical application for therapy development, and address challenges encountered by these studies toward precision oncology are discussed.
Abstract
Genome-wide association studies (GWAS) have emerged as a revolution in the discovery of genetic determinants underlying cancer susceptibility by revealing germline variants that influence risk, progression and treatment response. In recent years, large-scale GWAS consortia have identified thousands of cancer loci in a wide variety of tumor types and importantly have shed light on inherited risk for cancer and functional elements within the noncoding genome as major contributors to oncogenic processes. These discoveries have widened the horizon of cancer genetics beyond high-penetrance mutations by establishing and recognizing for the first time ever, gaining importance of cumulative effect of common low-effect alleles and polygenic risk. In addition, the integration of GWAS data with transcriptomic, epigenomic and proteomic information has expedited functional interpretation of risk loci revealing pathways involved in DNA repair, immune modulation, cell proliferation and hormone signaling. Aside from vulnerability, GWAS-based findings have also been serving to shape medical strategies, by revealing druggable targets, biomarkers for treatment selection and risk stratification models. However, challenges including missing heritability, lack of population representation, gene-environment interactions and poor clinical translation remain. In this review, we discuss the current GWAS findings in several common cancers, recent methodological and analytical developments of GWAS studies that help improve our understanding of cancer biology, knowledge gained from GWAS findings for potential clinical application for therapy development, and address challenges encountered by these studies toward precision oncology.
This work identified 709 variants mapping to 140 risk regions, that are associated with significant variation between REF and ALT alleles, that may influence breast cancer risk through expression of CCDC88C, which in turn could impact prognosis.
K. Mackie, H. Kemp, A. Gunnell et al.· HGG advances· 0 citations
Osteoarthritis (OA) affects more than 500 million people worldwide, yet disease-modifying therapies remain unavailable. Genome-wide association studies (GWAS) have transformed understanding of OA genetic susceptibility, progressing from early single-cohort analyses to multi-ancestry meta-analyses involving 2 million in...
Yue-Zhou Wu, Yang Hong, Xukun Lyu et al.· Journal of genetics and geno...· 0 citations
BACKGROUND
Genome-wide association studies (GWAS) have identified numerous lung cancer susceptibility loci based on single nucleotide polymorphisms (SNPs), yet a substantial proportion of heritability remains unexplained. We therefore evaluated germline copy number variants (CNVs) as an underexplored source of genetic...
Fei-Fei Xiao, Fei Qin, Xi-Zhi Luo et al.· Cancer Epidemiology, Biomark...· 0 citations
A cross-population genome-wide association meta-analysis of 11 GWAS summary-statistic datasets comprises 20,120 pancreatic cancer cases and 1,446,192 controls genetically similar to European or East Asian reference populations refine the genetic architecture of pancreatic cancer and provide insights into candidate gene...
Cutaneous melanoma is the deadliest skin cancer and is highly heritable, yet only 54 common risk loci have been identified. We conducted a large meta-analysis of melanoma GWAS, including 35 GWAS from 29 cohorts (69,871 cases; 1,616,233 controls) identifying 156 independent signals at 116 risk loci. We found a strong li...
G. Jayasinghe, Jian-Xin Shi, Rohit Thakur et al.· medRxiv· 0 citations
The reasons for the slow pace of the diffusion of polygenic risk scores, along with the related field of pharmacogenomics, may be useful in clinical practice for the prevention and treatment of common diseases are reviewed.
David J. Hunter, Michael Inouye· New England Journal of Medic...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.